All updated as on -
As of 2022, the total worth of the industry around the world was estimated at $2.6 billion. By the year 2030, it is expected to have surpassed US$ 5.1 bn, having grown at a CAGR of 7.4% between 2023 and 2030.
Using stem cells to repair and restore damaged heart tissue is the focus of cardiac stem cell therapy, a subfield of regenerative medicine. Stem cells are unspecialized cells that can differentiate into other cell types. Stem cells have found a number of applications in cardiology, including the repair of damaged heart muscle cells, the development of new blood arteries, and the enhancement of cardiac output. Bone marrow, adipose tissue, embryonic or induced pluripotent stem cells, and other tissues can all provide cardiac stem cells. Cardiovascular stem cell therapies have been the subject of numerous clinical trials to determine their safety and efficacy, and the results have been encouraging in terms of enhancing heart function and decreasing symptoms in patients with heart disease.
For optimal patient results, stem cell therapy should send the optimal number of cells to the optimal site at the optimal time for the maximum duration. Ejection fraction, mixed venous oxygen saturation (MVO2), objective measures of ischemia, and mortality are utilised by doctors as yardsticks for success. Patients often use more ethereal language when describing their desired outcomes, such as the elimination of chest discomfort, reduction of shortness of breath, enhancement of exercise tolerance, and lengthening of life. Stem cell therapy has the potential to improve patient outcomes regardless of the criteria used to evaluate it, and it is moving closer to becoming a reality.
The numerous variables responsible for the expansion of the cardiology stem cells market are collectively referred to as the market's growth factors. One of the key factors propelling this market forward is the worldwide rise in the incidence of cardiovascular disorders. According to the World Health Organisation (WHO), cardiovascular illnesses are the leading cause of death worldwide, accounting for over 17.9 million deaths annually. Because of this, there is a growing interest in cardiac stem cell therapy as a potential treatment for various diseases. Another major driver of expansion in the cardiology stem cells market is the rising expenditures on related R&D. There are a number of pharmaceutical and biotechnology firms that are spending significantly on R&D.
The field of regenerative medicine, which includes cardiology stem cells, has benefited greatly from the progress made in stem cell research. Reprogrammed adult cells, known as induced pluripotent stem cells (iPSCs), have the potential to differentiate into any cell type in the body. Using this method, we can develop patient-specific stem cell lines for use in personalised medicine, which has the potential to address some of the ethical problems raised by the use of embryonic stem cells.
Stem cell genetic material can be manipulated using the potent gene editing technology CRISPR/Cas9 to eliminate disease-causing mutations or introduce desirable characteristics. This innovation could significantly advance the fields of stem cell therapy and personalised medicine. Organoids are three-dimensional models that simulate the structure and function of real organs. Functional tissues can be produced using stem cells and scaffolds in a process known as tissue engineering. The advancement of personalised medicines and our knowledge of human physiology and illness stand to benefit greatly from these technological advances. New approaches to stem cell therapy delivery have emerged as a result of developments in biomaterials and microscale engineering.
Because of the high incidence of cardiovascular illness in the region, the established healthcare system, and the favourable regulatory climate, North America is now the largest market for cardiology stem cells. The United States is the leading economic force in North America, generating the lion's share of the region's total income. Due to a huge patient pool suffering from cardiovascular disorders and rising awareness and acceptance of stem cell therapy, the Asia Pacific region is poised to become a major player in the cardiology stem cell market in the future years. China and Japan are the two biggest economies in the Asia Pacific region.
Report Coverage
Global Cardiology Stem Cells research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Cardiology Stem Cells report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Cardiology Stem Cells competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Cardiology Stem Cells market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Cardiology Stem Cells market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Cardiology Stem Cells market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Astellas Pharma, Inc., STEMCELL Technologies, Cellular Engineering Technologies, BioTimes, Inc., Takara Bio, Inc., U.S. Stem Cell, Inc., BrainStorm Cell Limited., Cytori Therapeutics, Inc., Lisata Therapeutics, Bio Cardia, Inc.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Cardiology Stem Cells market based on the below-mentioned segments:
Global Cardiology Stem Cells Market, By Type of Cell
Embryonic Stem Cells
Adult Stem Cells
Induced Pluripotent Stem Cells
Cord Blood Stem Cells and Amniotic Fluid Stem Cells
Global Cardiology Stem Cells market, By Application
Heart Failure
Myocardial Infarction
Critical Limb Ischemia
Others
Global Cardiology Stem Cells Market, By End User
Pharmaceutical & Biotechnology Companies
Hospitals & Cell Banks
Academic & Research Institutes
Global Cardiology Stem Cells market, Regional Analysis
Using stem cells to repair and restore damaged heart tissue is the focus of cardiac stem cell therapy, a subfield of regenerative medicine. Stem cells are unspecialized cells that can differentiate into other cell types. Stem cells have found a number of applications in cardiology, including the repair of damaged heart muscle cells, the development of new blood arteries, and the enhancement of cardiac output. Bone marrow, adipose tissue, embryonic or induced pluripotent stem cells, and other tissues can all provide cardiac stem cells. Cardiovascular stem cell therapies have been the subject of numerous clinical trials to determine their safety and efficacy, and the results have been encouraging in terms of enhancing heart function and decreasing symptoms in patients with heart disease.
For optimal patient results, stem cell therapy should send the optimal number of cells to the optimal site at the optimal time for the maximum duration. Ejection fraction, mixed venous oxygen saturation (MVO2), objective measures of ischemia, and mortality are utilised by doctors as yardsticks for success. Patients often use more ethereal language when describing their desired outcomes, such as the elimination of chest discomfort, reduction of shortness of breath, enhancement of exercise tolerance, and lengthening of life. Stem cell therapy has the potential to improve patient outcomes regardless of the criteria used to evaluate it, and it is moving closer to becoming a reality.
The numerous variables responsible for the expansion of the cardiology stem cells market are collectively referred to as the market's growth factors. One of the key factors propelling this market forward is the worldwide rise in the incidence of cardiovascular disorders. According to the World Health Organisation (WHO), cardiovascular illnesses are the leading cause of death worldwide, accounting for over 17.9 million deaths annually. Because of this, there is a growing interest in cardiac stem cell therapy as a potential treatment for various diseases. Another major driver of expansion in the cardiology stem cells market is the rising expenditures on related R&D. There are a number of pharmaceutical and biotechnology firms that are spending significantly on R&D.
The field of regenerative medicine, which includes cardiology stem cells, has benefited greatly from the progress made in stem cell research. Reprogrammed adult cells, known as induced pluripotent stem cells (iPSCs), have the potential to differentiate into any cell type in the body. Using this method, we can develop patient-specific stem cell lines for use in personalised medicine, which has the potential to address some of the ethical problems raised by the use of embryonic stem cells.
Stem cell genetic material can be manipulated using the potent gene editing technology CRISPR/Cas9 to eliminate disease-causing mutations or introduce desirable characteristics. This innovation could significantly advance the fields of stem cell therapy and personalised medicine. Organoids are three-dimensional models that simulate the structure and function of real organs. Functional tissues can be produced using stem cells and scaffolds in a process known as tissue engineering. The advancement of personalised medicines and our knowledge of human physiology and illness stand to benefit greatly from these technological advances. New approaches to stem cell therapy delivery have emerged as a result of developments in biomaterials and microscale engineering.
Because of the high incidence of cardiovascular illness in the region, the established healthcare system, and the favourable regulatory climate, North America is now the largest market for cardiology stem cells. The United States is the leading economic force in North America, generating the lion's share of the region's total income. Due to a huge patient pool suffering from cardiovascular disorders and rising awareness and acceptance of stem cell therapy, the Asia Pacific region is poised to become a major player in the cardiology stem cell market in the future years. China and Japan are the two biggest economies in the Asia Pacific region.
Report Coverage
Global Cardiology Stem Cells research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Cardiology Stem Cells report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Cardiology Stem Cells competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Cardiology Stem Cells market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Astellas Pharma, Inc., STEMCELL Technologies, Cellular Engineering Technologies, BioTimes, Inc., Takara Bio, Inc., U.S. Stem Cell, Inc., BrainStorm Cell Limited., Cytori Therapeutics, Inc., Lisata Therapeutics, Bio Cardia, Inc. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Cardiology Stem Cells Market from 2021 to 2030.
- Market Forecast for Cardiology Stem Cells Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Cardiology Stem Cells competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Cardiology Stem Cells
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Cardiology Stem Cells market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Cardiology Stem Cells market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Astellas Pharma, Inc., STEMCELL Technologies, Cellular Engineering Technologies, BioTimes, Inc., Takara Bio, Inc., U.S. Stem Cell, Inc., BrainStorm Cell Limited., Cytori Therapeutics, Inc., Lisata Therapeutics, Bio Cardia, Inc.
Primary Target Market
- Market Players of Cardiology Stem Cells
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Cardiology Stem Cells market based on the below-mentioned segments:
Global Cardiology Stem Cells Market, By Type of Cell
Embryonic Stem Cells
Adult Stem Cells
Induced Pluripotent Stem Cells
Cord Blood Stem Cells and Amniotic Fluid Stem Cells
Global Cardiology Stem Cells market, By Application
Heart Failure
Myocardial Infarction
Critical Limb Ischemia
Others
Global Cardiology Stem Cells Market, By End User
Pharmaceutical & Biotechnology Companies
Hospitals & Cell Banks
Academic & Research Institutes
Global Cardiology Stem Cells market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive cardiology stem cells market market research and competitor analysis for your business to help you develop more profound insights into the cardiology stem cells market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the cardiology stem cells market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.